S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
One company did the impossible with AI (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
One company did the impossible with AI (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
HUGE BUY ALERT: Move Fast, Musk… (Ad)
What to watch for as China's major political meeting of the year gets underway

Biodesix (BDSX) Competitors

$1.58
+0.04 (+2.60%)
(As of 03/1/2024 ET)

BDSX vs. GTH, HHLA, MDXH, ENZ, PSNL, DMTK, RNLX, XGN, AKUMQ, and CNTG

Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Genetron (GTH), HH&L Acquisition (HHLA), MDxHealth (MDXH), Enzo Biochem (ENZ), Personalis (PSNL), DermTech (DMTK), Renalytix (RNLX), Exagen (XGN), Akumin (AKUMQ), and Centogene (CNTG). These companies are all part of the "medical laboratories" industry.

Biodesix vs.

Genetron (NASDAQ:GTH) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

Genetron has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Biodesix has a consensus price target of $3.50, suggesting a potential upside of 121.52%. Given Genetron's higher probable upside, analysts plainly believe Biodesix is more favorable than Genetron.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genetron
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Biodesix
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Biodesix received 22 more outperform votes than Genetron when rated by MarketBeat users. Likewise, 70.59% of users gave Biodesix an outperform vote while only 33.33% of users gave Genetron an outperform vote.

CompanyUnderperformOutperform
GenetronOutperform Votes
2
33.33%
Underperform Votes
4
66.67%
BiodesixOutperform Votes
24
70.59%
Underperform Votes
10
29.41%

10.7% of Genetron shares are held by institutional investors. Comparatively, 21.2% of Biodesix shares are held by institutional investors. 63.8% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biodesix has lower revenue, but higher earnings than Genetron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$94.34M1.31-$117.21MN/AN/A
Biodesix$38.21M3.74-$65.45M-$0.90-1.76

In the previous week, Biodesix had 6 more articles in the media than Genetron. MarketBeat recorded 9 mentions for Biodesix and 3 mentions for Genetron. Biodesix's average media sentiment score of 0.94 beat Genetron's score of 0.50 indicating that Genetron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genetron
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biodesix
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genetron has a net margin of 0.00% compared to Genetron's net margin of -143.88%. Biodesix's return on equity of 0.00% beat Genetron's return on equity.

Company Net Margins Return on Equity Return on Assets
GenetronN/A N/A N/A
Biodesix -143.88%-1,387.19%-68.59%

Summary

Biodesix beats Genetron on 10 of the 15 factors compared between the two stocks.


Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDSX vs. The Competition

MetricBiodesixMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$142.96M$1.89B$5.21B$7.62B
Dividend YieldN/A1.81%2.82%3.87%
P/E Ratio-1.768.19257.3718.81
Price / Sales3.74157.613,092.04110.79
Price / CashN/A382.8799.8655.35
Price / Book5.852.754.534.54
Net Income-$65.45M-$122.90M$114.95M$211.55M
7 Day PerformanceN/A2.64%5.72%3.36%
1 Month Performance-25.47%8.35%12.81%6.70%
1 Year Performance-21.00%-14.88%12.92%7.44%

Biodesix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GTH
Genetron
0 of 5 stars
$3.83
+0.5%
N/A+33.3%$121.11M$94.34M0.00993Short Interest ↑
HHLA
HH&L Acquisition
0 of 5 stars
$10.75
-0.3%
N/A+5.0%$156.52MN/A-76.78N/A
MDXH
MDxHealth
2.5801 of 5 stars
$3.49
-2.8%
$66.67
+1,813.0%
-89.8%$95.10M$63.69M-1.88252Upcoming Earnings
Short Interest ↓
ENZ
Enzo Biochem
0 of 5 stars
$1.36
-0.7%
N/A+17.7%$68.41M$31.06M0.00179Short Interest ↑
News Coverage
Gap Up
High Trading Volume
PSNL
Personalis
4.3117 of 5 stars
$1.26
-7.4%
$4.93
+291.5%
-35.5%$61.78M$65.05M-0.53395Analyst Report
News Coverage
Gap Up
DMTK
DermTech
1.1663 of 5 stars
$1.25
-6.0%
$5.50
+340.0%
-77.1%$42.80M$14.52M-0.36278Analyst Revision
News Coverage
Gap Down
RNLX
Renalytix
2.3258 of 5 stars
$0.75
-11.8%
$5.00
+566.7%
-69.2%$37.48M$3.40M-1.67102Short Interest ↑
Gap Down
XGN
Exagen
4.8896 of 5 stars
$2.11
-1.4%
$5.50
+160.7%
-14.4%$35.98M$45.56M-1.13199Short Interest ↓
News Coverage
AKUMQ
Akumin
0 of 5 stars
$0.38
-6.3%
N/AN/A$34.19M$749.63M-0.133,631Gap Down
CNTG
Centogene
4.1131 of 5 stars
$0.91
+2.2%
$1.50
+64.5%
-31.4%$24.70M$50.03M0.00444News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:BDSX) was last updated on 3/3/2024 by MarketBeat.com Staff